Expertise in
2
conditions

Vincent Castonguay

Quebec, QC, CA 
Expertise in
2
conditions
Quebec, QC, CA 

Overview

Vincent Castonguay practices practicing medicine in Quebec, Canada.

Mr. Castonguay is highly rated in 2 conditions, according to our data. His clinical expertise encompasses Renal Cell Carcinoma (RCC), Cervical Cancer, Ovarian Cancer, Systemic Capillary Leak Syndrome, and Nephrectomy.

He is actively involved in clinical research, co-authoring 35 peer reviewed articles and participating in 3 clinical trials.

Gender

Male

Locations

Quebec, QC, Canada
Other Locations
Canada

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A Phase III Study Comparing Single-Agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-Based Chemotherapy in Women With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
A Phase III Study Comparing Single-Agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-Based Chemotherapy in Women With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: July 31, 2026
Intervention Type: Drug, Procedure, Other
Study Drugs: Carboplatin, Cediranib Maleate, Gemcitabine, Gemcitabine Hydrochloride, Olaparib, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride
Study Phase: Phase 3
A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)
A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)
Enrollment Status: Active_not_recruiting
Publish Date: July 01, 2026
Intervention Type: Procedure, Drug, Other
Study Drugs: Cediranib, Cediranib Maleate, Olaparib, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride, Topotecan, Topotecan Hydrochloride
Study Phase: Phase 2/Phase 3
A Phase 2, Open-label, Multicenter, Study of an Immunotherapeutic Treatment, DPX-Survivac in Combination With Low Dose Cyclophosphamide and Pembrolizumab, in Subjects With Selected Advanced and Recurrent Solid Tumours.
A Phase 2, Open-label, Multicenter, Study of an Immunotherapeutic Treatment, DPX-Survivac in Combination With Low Dose Cyclophosphamide and Pembrolizumab, in Subjects With Selected Advanced and Recurrent Solid Tumours.
Enrollment Status: Active_not_recruiting
Publish Date: March 31, 2022
Intervention Type: Other, Drug
Study Drugs: Cyclophosphamide, Pembrolizumab
Study Phase: Phase 2
View 2 Less Clinical Trials

35 Total Publications

Trajectory timelines and treatment efficacy of 177Lu-PSMA-617 radioligand therapy for metastatic castration-resistant prostate cancer Real-world data from 50 consecutive cases treated in a single Canadian center.
Trajectory timelines and treatment efficacy of 177Lu-PSMA-617 radioligand therapy for metastatic castration-resistant prostate cancer Real-world data from 50 consecutive cases treated in a single Canadian center.
Journal: Canadian Urological Association journal = Journal de l'Association des urologues du Canada
Published: February 17, 2026

Frequently Asked Questions about Vincent Castonguay

Is Vincent Castonguay a top-rated expert for Renal Cell Carcinoma (RCC)?

MediFind is an objective health platform that identifies experts based on real-world data. Vincent Castonguay is classified as an Advanced expert for Renal Cell Carcinoma (RCC), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Vincent Castonguay participate in research or clinical trials?

Yes. Vincent Castonguay has published 35 articles and abstracts on conditions like Renal Cell Carcinoma (RCC). You can view a list of Vincent Castonguay's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Castonguay's expertise for a condition
ConditionClose
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile